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Khalil Choucair1, Joshua Ejdelman1, Fadi Brimo2, Armen Aprikian1, Simone Chevalier1 and Jacques Lapointe1*Abstract
Background: Prostate cancer (PCa), a leading cause of cancer death in North American men, displays a broad
range of clinical outcome from relatively indolent to lethal metastatic disease. Several genomic alterations have
been identified in PCa which may serve as predictors of progression. PTEN, (10q23.3), is a negative regulator of the
phosphatidylinositol 3-kinase (PIK3)/AKT survival pathway and a tumor suppressor frequently deleted in PCa. The
androgen receptor (AR) signalling pathway is known to play an important role in PCa and its blockade constitutes a
commonly used treatment modality. In this study, we assessed the deletion status of PTEN along with AR
expression levels in 43 primary PCa specimens with clinical follow-up.
Methods: Fluorescence In Situ Hybridization (FISH) was done on formalin fixed paraffin embedded (FFPE) PCa
samples to examine the deletion status of PTEN. AR expression levels were determined using
immunohistochemistry (IHC).
Results: Using FISH, we found 18 cases of PTEN deletion. Kaplan-Meier analysis showed an association with disease
recurrence (P=0.03). Concurrently, IHC staining for AR found significantly lower levels of AR expression within those
tumors deleted for PTEN (P<0.05). To validate these observations we interrogated a copy number alteration and
gene expression profiling dataset of 64 PCa samples, 17 of which were PTEN deleted. We confirmed the predictive
value of PTEN deletion in disease recurrence (P=0.03). PTEN deletion was also linked to diminished expression of
PTEN (P<0.01) and AR (P=0.02). Furthermore, gene set enrichment analysis revealed a diminished expression of
genes downstream of AR signalling in PTEN deleted tumors.
Conclusions: Altogether, our data suggest that PTEN deleted tumors expressing low levels of AR may represent a
worse prognostic subset of PCa establishing a challenge for therapeutic management.
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Prostate cancer (PCa) strongly affects the male popula-
tion, and is classified as the most commonly diagnosed
cancer and a leading cause of cancer death in North
American men [1]. The current prognostic tools, such as
pre-operative prostate specific antigen (PSA) levels,
histological Gleason grading of biopsy specimens and
clinical TNM (tumor, node, metastasis) staging seem un-
able to accurately risk stratify individual PCa patients at* Correspondence: jacques.lapointe@mcgill.ca
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reproduction in any medium, provided the orearly stages of the disease. Given the wide range of clin-
ical outcomes and the heterogeneity of the disease, the
main challenge facing physicians remains to distinguish
latent from clinically significant tumors. There is thus a
clear need for better prognostic markers.
Androgens are required for maintaining the homeosta-
sis of the normal prostate epithelium. Their effect is
mediated via the androgen receptors (AR), a member of
the nuclear superfamily of steroid receptor, acting as a
transcription factor in prostate cell nuclei. PCa cells have
retained the ability to proliferate upon stimulation with
androgens, resulting in tumor growth [2]. Thus, PCa
patients that experience a recurrence following localizedal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinicopathologic parameters of the study
subjects
n=43
Median age (range, years) 63 (47–76)
Median follow-up (months) 62
Median PSA at surgery (ng.ml-1) 8.7
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Although most patients respond well initially to andro-
gen deprivation therapy, almost all of them will eventu-
ally experience resistance to treatment and disease
progression [3]. Therapeutic options for castrate resist-
ant PCa (CRPC) are limited to chemotherapy regimens
that show a modest survival benefit [4]. There is cur-
rently no curative treatment for metastatic PCa. Under-
standing the molecules and the pathways involved in
mediating resistance is thus needed for a better clinical
management of the disease.
The phosphatidylinositol 3-kinase (PI3K)/AKT signal
transduction pathway contributes to cancer growth and
survival, and is activated in a broad range of human ma-
lignancies including PCa [5]. The phosphatase and ten-
sin homologue deleted on chromosome 10 (PTEN) is a
tumor suppressor gene on 10q23.3 locus that acts by
negatively regulating the PI3K/AKT pathway [6]. In ani-
mal models, PTEN was shown to be haploinsufficient in
tumor suppression [7]. PTEN genomic deletion has been
detected in human tissues representing all stages of PCa
development and progression including High Grade
Prostatic Intraepithelial Neoplasia (HGPIN), primary
PCa and at higher frequency in metastatic PCa and
CRPC [8-15]. Using Fluorescent in situ hybridization
(FISH), PTEN deletion status of primary PCa has been
associated with poor outcome [14]. Previous studies in
human PCa cell lines and mice models have suggested
that inactivation of PTEN and PI3K/AKT activation can
modulate AR activity and contribute to CRPC [16-18].
These observations provided further rationale to exam-
ine PTEN and AR in human prostate tissues.
In this study, we surveyed PCa samples for genomic
DNA copy number alterations (CNAs) of the PTEN gene
using Fluorescent in situ hybridization (FISH) and AR ex-
pression by immunohistochemistry (IHC). An existing PCa
microarray dataset of DNA CNAs by array comparative
genomic hybridization (CGH) and corresponding gene ex-
pression profiling were used to validate these findings.
Methods
Ethics statement
This study was conducted with the written consent of the
participants and approved by the Research Ethics Board of
the McGill University Health Centre (study BMD-10-115).
Tissue samples
Formalin fixed paraffin embedded (FFPE) blocks (n = 43)
of primary tumors and adjacent benign tissues from radical
prostatectomy were retrieved from the Department of
Pathology. Duplicate tissue cores (1mm diameter) were
assembled into tissue microarrays (TMAs). Haematoxylin
and eosin (H&E)-stained TMA sections were reviewed to
determine the presence of representative areas of theoriginal samples. The clinicopathologic features of the co-
hort are summarized in Table 1. Recurrence-free interval
was defined as the time between date of surgery and the
date of first PSA increase >0.2ng/ml or the date of last
follow-up without PSA increase (censored). Kaplan-Meier
survival analysis (log-rank test) was performed using
WinStat (R. Fitch Software).Fluorescent in situ hybridization (FISH)
Dual-color FISH was carried out on TMA sections using
the BAC clone RP11-383D9 (BACPAC Resources Center,
Oakland, CA) mapping to the PTEN gene on chromo-
some 10q23.3 region and the commercially available
CEP10 Spectrum Green probe (CEP 10, Abbott
Molecular, Abbott Park, IL), which spans the 10p11.1-
q11.1 centromeric region. RP11-383D9 DNA was la-
beled with Spectrum Orange-dUTP (Enzo Life Science,
Farmingdale, NY) using the Nick Translation Reagent
Kit (Abbott Molecular). The 5 μm TMAs sections were
de-paraffinized in 6 changes of xylene before
immersion in 95% ethanol. The slides were then placed
in 0.2 N HCl solution at room temperature (RT°) for
20 min followed by a 2-hour incubation at 80°C in 10
mM citric acid buffer (pH 6) for pre-treatment. Speci-
mens were digested in 0.1 mg/ml protease I (Abbott
Molecular), and then fixed for 10 min in formalin be-
fore dehydration in an ethanol series. The two probes
and target DNA were co-denatured at 73°C for 6 min
and left to hybridize at 37°C O/N using the Thermo-
Brite system (Abbott Molecular). Post-hybridization
washes were performed in 2xSSC and 0.3% NP40/
0.4xSSC at 73°C for 2 min and 1 min respectively, fol-
lowed by a 30 sec incubation at RT° in 2xSSC.FISH data analysis
In order to evaluate the 10q23.3 copy number, we counted
fluorescent signals in 100 non-overlapping interphase
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(DAPI III, Abbott Molecular) staining of nuclei with
reference to the corresponding H&E-stained tissue iden-
tified the areas of adenocarcinoma. Using hybridization
in 30 benign control cores, 10q23.3 deletion was defined
as ≥15% (mean + 3 standard deviation in non-neoplastic
controls as described [19,20]) of tumor nuclei containing
one or no 10q23.3 locus signal and by the presence
of two CEP10 signals. Images were acquired with an
Olympus IX-81 inverted microscope at 96X magnification
using ImageProPlus 7.0 software (MediaCybernetics,










Figure 1 Dual color FISH analysis of PTEN deletion in primary PCa. A)
labelled and co-hybridized with fluorescent Centromere 10 control probe t
43 primary PCa samples determined by FISH. C) FISH for PTEN status in rep
the FISH image shows 1 red signal (10q23.3 locus) and two green signals (
panel, the FISH image shows two red signals and two green signals in theImmunohistochemistry (IHC) staining
Immunostaining of AR on TMAs sections was per-
formed using a mouse anti-AR antibody (N-terminal AR
441, NeoMarker, Fremont, CA) and the Envision detec-
tion kit (Dako, Carpinteria, CA). The 5 μm TMAs sec-
tions were de-paraffinized in a series of xylene and
hydrated in a graded series ethanol solutions. Heat-
induced antigen retrieval was performed by immersing
the slides in 10 mM citric acid buffer solution (pH 6)
and boiling for 30 min using microwave energy. The
slides were left in solution to cool down for 30 min at
room temperature. Endogenous peroxydase activity wasProstate Cancer,  PTEN Non-Deleted
18 (42% ) 
TEN D ele ted
25 (58% )
PTEN Non-D e le ted
BAC DNA mapping to chromosome 10q23.3 (PTEN) was fluorescently
o detect PTEN deletion in tumor samples. B) PTEN deletion status of
resentative interphase nuclei of prostate samples. On the left panel,
centromere 10) per nuclei indicating a PTEN deletion. On the right
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Figure 2 Prognostic value of PTEN deletion in PCa. Kaplan-Meier recurrence-free survival analysis based on PTEN deletion status determined
by FISH (n=43). P-value (log-rank test) indicated.
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10% normal goat serum in PBS (Dako), the primary anti-
body (1:50 dilution in Dako antibody diluent) was used
for two hours at room temperature. Chromogenic detec-
tion was carried out using a peroxidase-conjugated sec-
ondary antibody (30 min) and DAB reagents (10 min)
provided with the Envision detection kit. Tissue sections
were counterstained with Meyer’s Haematoxylin (Thermo
Scientific, Waltham, MA).Figure 3 AR IHC staining of PCa. Examples of nuclear AR staining corresp
B=28, C=71 and D=76. Original magnification 200X.IHC data analysis
Nuclear staining was assessed by two independent obser-
vers using the H-score method described in [21,22].
Briefly, H-score was obtained by computing the product
of staining intensity (i=0-3) and the proportion of cells
with the specific intensity (0–100), in areas of adenocar-
cinoma as identified with reference to the corresponding
H&E-stained tissue. The H-scores were adjusted to give

































Figure 4 PTEN deletion is associated with low AR expression in
PCa. Adjusted H-score of nuclear AR (IHC) was compared between
PCa with and without PTEN deletion determined by FISH. The box-
plot shows the mean (+ sign), the 25th, 50th (median), 75th
percentiles of AR H-score including the minimum and maximum
(two-sided Mann–Whitney U-test, P-value indicated).
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mens categories with the Mann–Whitney U-Test (http://
elegans.som.vcu.edu/~leon/stats/utest.html).
Gene set enrichment analysis (GSEA)
Analysis [23] was performed using GSEA software ver-
sion 2.07 (Broad Institute, Cambridge, MA) with the
previously published gene expression data of 64 prostate
tumors by Lapointe et al. [24] stratified by their PTEN
genomic status as reported in the corresponding array
CGH study [9]. Two androgen-responsive gene sets
(R1881-treated LNCaP cells) were tested for enrichment
in the gene expression microarray data: a curated set of
82 genes (NELSON_RESPONSE_TO_ANDROGEN_UP,
[25]) from the Molecular Signatures database (MSigDB,
C2) and a set of 207 genes reported by DePrimo et al.
[26]. Lapointe et al gene expression study used for GSEA
included data for respectively 71 and 204 genes of Nelson
et al. and DePrimo et al. androgen-responsive gene
sets. A thousand permutations were done and the false
discovery rate (FDR) was estimated.
Results
FISH analysis and PTEN deletion status
We used FISH to assess the genomic status of PTEN at
chromosome 10q23.3 on TMAs representing 43 cases of
human PCa with clinical follow-up. The clinicopatholo-
gic characteristics of the study subjects are summarized
in Table 1. We found that 18 of 43 tumors harbor a
hemizygous deletion of PTEN (Figure 1). No homozy-
gous deletion was detected in these samples. We did not
find any significant association between PTEN status
and tumor Gleason score, surgical stage, and preopera-
tive PSA levels of patients (data not shown). To further
evaluate the clinical significance of the PTEN deletion,
we stratified the 43 cases based on their PTEN deletion
status and performed a Kaplan-Meier survival analysis.
Figure 2 shows that PTEN deletion was associated with
a significant shorter time to recurrence (P=0.03).
IHC and AR expression
We used the same set of tumors to estimate the levels of
nuclear AR expression by IHC. For each sample, the
H-score was calculated to take into account the propor-
tion of stained cells on the TMA cores as well as the in-
tensity of the nuclear staining. The range of the H-score
adjusted to 100 varied across the samples from 10 to 100
(median=70, n=43). AR immunostaining of specimens
with different H-scores are shown as examples in Figure 3.
In these samples, AR immunostaining was not signifi-
cantly associated with the Gleason score, surgical stage,
preoperative PSA, and recurrence (not shown). However
we found that the AR expression was significantly
lower in PCa tumors harboring a PTEN deletioncompared to those with no deletion of PTEN (P<0.05,
Figure 4).
PTEN deletion and AR expression in gene expression
and DNA copy number alterations dataset
To confirm our observations, we examined a previously
published PCa gene expression study [24], for which the
PTEN deletion status was assessed by array CGH [9].
This independent data set of 64 PCa samples included
29 cases with clinical follow-up. We found that 17 of
64 tumors harbor a deletion of PTEN which was signifi-
cantly associated with a reduced levels of PTEN mRNA
(P<0.01, Figure 5A). A Kaplan-Meier survival analysis
performed on the 29 cases with clinical follow-up
revealed that the PTEN deletion was associated with
early disease recurrence (P=0.03, Figure 5B). The PTEN
deletion was also associated with a reduced levels of AR
mRNA (P=0.02, Figure 6). However, AR mRNA levels
did not predict biochemical recurrence in these samples
(data not shown).
Androgen-regulated genes and PTEN deletion
To assess whether the reduced AR levels of expression
observed in PTEN deleted tumors had consequences on
AR signalling, we performed GSEA on the microarray data

























































Figure 5 PTEN deletion predicts disease recurrence in an independent PCa cohort. A) In the dataset of Lapointe et al., PTEN deletion status
of 64 PCa as determined by array CGH was associated with low PTEN mRNA levels measured by gene expression profiling. The box-plot shows the
mean (+ sign), the 25th, 50th (median), 75th percentiles of PTEN expression including the minimum and maximum (unequal variance t-test, P-
Value indicated). Values are reported as log2 ratios, normalized to the sample-set mean. B) Kaplan-Meier analysis of recurrence-free survival based
on PTEN deletion status of a subset of the PCa cohort for which the clinical follow-up was available (n=29). P-value (log-rank test) indicated.
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an a priori defined set of genes shows statistically signifi-
cant, concordant differences between two phenotypes
[23], in our case the PTEN status. We first tested a































Figure 6 PTEN deletion is associated with low AR expression in
an independent PCa cohort. PTEN deletion status as determined
by array CGH was associated with low AR mRNA levels as measured
by gene expression profiling of 64 PCa cases from the dataset of
Lapointe et al. The box-plot shows the mean (+ sign), the 25th, 50th
(median), 75th percentiles of AR expression including the minimum
and maximum (unequal variance t-test, P-value indicated). Values are
reported as log2 ratios, normalized to the sample-set mean.(MSigDB,C2) identified as NELSON_RESPONSE_TO_
ANDROGEN_UP, [25]. The plot in Figure 7A shows
the significant enrichment of the AR-regulated genes in
tumors with no deletion of PTEN compared to those with
a deletion (FDR of 0.01). To further confirm this result,
we tested a second set of androgen regulated genes
reported by DePrimo et al. [26] and found also an enrich-
ment of expression of these genes in tumors with no
PTEN deletion (FDR=0.13, Figure 7B). Genes from Nelson
et al. that significantly contribute to the enrichment core
are shown in Figure 7C.
Discussion
In this study, we have shown in two independent sets of
PCa samples that the PTEN genomic deletion was asso-
ciated with early disease recurrence and reduced levels
of AR expression. In microarray gene expression data,
the PTEN deletion was also associated with a down
regulation of AR-driven genes.
The frequency of PTEN deletion in our FISH study
(40%) is within the range of previous reports
[8,10,12,14,15]. Our survival analysis further confirms
the association of PTEN genomic deletion and poor out-
come of PCa reported earlier [14] and its potential use
as a prognostic marker. Clinical relevance is also sup-
ported by the recent literature detecting PTEN deletion
at high frequency in CRPC samples [11], in circulating
tumor cells [27] and its association with PCa death
[11,28]. Further validation in larger cohorts would be
critical to compare its predictive value with the current
prognostication tools.
The intriguing finding of our study was the reduced
levels of AR expression quantified by H-score in tumors




















































































Nelson et al. 
FDR = 0.01











Figure 7 PTEN status is associated with AR signalling. GSEA was performed with previously published gene expression data of 64 prostate
tumors (Lapointe et al.) stratified by their PTEN genomic status. Two androgen responsive gene sets were tested: A) a curated set of 71 genes
(NELSON_RESPONSE_TO_ANDROGEN_UP, Nelson et al.) from the Molecular Signatures database (MSigDB, C2) and B) a set of 204 genes reported
by DePrimo et al. GSEA identified enrichment of androgen responsive genes in PTEN positive samples. The enrichment score (ES, y-axis) reflects the
degree to which an androgen responsive gene set is overrepresented at the top ranked list of genes according to the PTEN status (ranked in
descending order from left to right, x-axis). Enrichment is evidenced by the early positive deflection of the running sum curve (blue line).
A thousand permutations were done and the false discovery rate estimated (FDR). C) Genes from Nelson et al. that contribute to the enrichment core.
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levels in a PCa microarray dataset. The differential
expression of AR according to the PTEN tumor status
has not been well documented so far. A pilot IHC study
has found a positive correlation between AR and PTEN
expression [29]. In contrast, Sircar et al. reported a posi-
tive correlation between PTEN deletion status and AR
expression [11] in CRPC samples. These results likely re-
flect two different stages of the disease: CRPC and un-
treated PCa. The genomic amplification of AR is known
to occur in CRPC but rarely in untreated PCa [30],
thereby explaining differences in results.
Previous in vitro studies in cell lines derived from
advanced PCa suggested that PTEN could act as sup-
pressor of AR activity [31,32]. It was also reported
that the activation of PI3K/AKT pathway can sup-
press the AR activity in low passage LNCaP and en-
hance AR activity in high passage, hence suggesting
modulation as cells evolve towards less responsivestatus [33]. In models representing less advanced dis-
ease, re-expression of PTEN in PTEN null murine
cells did not affect AR expression, but upregulated
the AR transcriptional activity [34]. Another group
reported that PTEN null murine prostate cells had a
reduced AR protein levels compared to wild-type
PTEN cells and the AR protein levels were partly
restored by the PI3K/mTOR inhibitor BEZ235 [35].
The latter observation would suggest that the activa-
tion of PI3K pathway may in part explain the reduced
AR levels in PTEN deleted tumors. A shown by Lin
et al., it is also possible that PTEN interacts directly
with AR and promotes its degradation [31]. Under-
lying mechanisms of how PTEN deletion in human
tumors is associated with lower AR expression and
transcriptional activity need to be further explored.
Given their reduced levels of AR expression, the
PTEN deleted tumor cells are expected to be less re-
sponsive to androgen ablation treatment. In support of
Choucair et al. BMC Cancer 2012, 12:543 Page 8 of 9
http://www.biomedcentral.com/1471-2407/12/543this hypothesis, it was reported that CRPC and early
biochemical recurrence were associated with reduced
immunoreactivity of PTEN and AR in the PCa samples
harvested before treatment initiation [29]. The addition
of an inhibitor of PI3K/mTOR to the standard andro-
gen ablation treatment of advanced PCa may therefore
be beneficial to patients with PTEN deleted tumor.
Some previous studies have found that low levels of
AR were associated with PCa recurrence [36,37] while
others reported the opposite [38,39]. In our study, AR
levels of expression were not significantly associated
with PCa recurrence. The antibody used, IHC technique
and scoring methods may explain the differences in the
findings. Given the limited number of patients of our
study, a detailed analysis of AR and PTEN in a large co-
hort of patients with follow-up is warranted.
During the course of our study, two groups also
showed a reduced expression of androgen regulated
genes in human PTEN deleted PCa by microarray ana-
lysis [34,35]. In our analysis, the androgen regulated
genes enriched in tumor with no deletion of PTEN in-
clude genes expressed in normal prostate luminal epi-
thelium such as KLK3 (PSA), TMPRSS2, and NKX3-1.
Of interest, the list includes AZGP1 previously reported
as a surrogate marker for subtype-1 tumors, a favourable
prognostic subclass of PCa defined by gene expression
pattern analysis [24]. AZGP1 prognostic value was fur-
ther confirmed by two other studies [40,41]. Previous
GSEA has also revealed enrichment of androgen-
responsive genes in subtype-1 tumors [42]. Consistant
with our findings, the confirmation of intact PTEN sta-
tus in subtype-1 tumors from the array CGH data may,
at least in part, explain their androgen-regulated gene
expression feature and good clinical outcome.
Conclusions
Although limited by the small sample size of this study,
our preliminary data support that PTEN deletion is asso-
ciated with PCa recurrence and may thus serve as prog-
nostic marker. As proposed, the low expression of AR
and its target genes associated with PTEN deletion may
have consequences on response to androgen ablation
therapy and may be an indication for the introduction of
additional therapeutic modalities.
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